Efficient Expression of a Transgene in Platelets Using Simian Immunodeficiency Virus-based Vector Harboring Glycoprotein Ibalpha Promoter: in Vivo Model for Platelet-targeting Gene Therapy.
From: Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Minamikawachi, Tochigi 329-0498, Japan.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- Publish Date: Jul 2006
- ISSN: 1530-6860
- Volume: 20
- Issue: 9
- Pages: 1522-4
- Medium: Internet
- Language: English
- Citation (JAMA): Ohmori Tsukasa, Mimuro Jun, Takano Katsuhiro, et al. Efficient Expression of a Transgene in Platelets Using Simian Immunodeficiency Virus-based Vector Harboring Glycoprotein Ibalpha Promoter: in Vivo Model for Platelet-targeting Gene Therapy.. FASEB J. Jul 2006;20:1522-4
Abstract
Platelets release several mediators that modify vascular integrity and hemostasis. In the present study, we developed a technique for efficient transgene expression in platelets in vivo and examined whether this targeted-gene-product delivery system using a platelet release reaction could be exploited for clinical applications. Analysis of luciferase reporter gene constructs driven by platelet-specific promoters (the GPIIb, GPIbalpha, and GPVI) revealed that the GPIbalpha promoter was the most potent in the megakaryoblastic cell line UT-7/TPO and human CD34+-derived megakaryocytes. Transduction of UT-7/TPO; CD34+-derived megakaryocytes; and c-Kit+, ScaI+, and Lineage- (KSL) murine hematopoietic stem cells with a simian immunodeficiency virus (SIV)-based lentiviral vector carrying eGFP resulted in efficient, dose-dependent expression of eGFP, and the GPIbalpha promoter seemed to bestow megakaryocytic-specific expression. Transplantation of KSL cells transduced with SIV vector containing eGFP into mice showed that there was preferable expression of eGFP in platelets driven by the GPIbalpha promoter [7-11% for the cytomeglovirus (CMV) promoter, 16-27% for the GPIbalpha promoter]. Furthermore, transplantation of ex vivo-transduced KSL cells by SIV vector carrying human factorVIII (hFVIII) driven by the GPIbalpha promoter induced the production of detectable transcripts of the hFVIII gene and the hFVIII antigen in bone marrow and spleen for at least 90 days and partially corrected the hemophilia A phenotype. Platelet-targeting gene therapy using SIV vectors appears to be promising for gene therapy approaches toward not only inherited platelet diseases but also other hemorrhagic disorders such as hemophilia A.
Mesh Headings (Keywords): Animals, Blood Platelets, Cell Differentiation, Cell Line, Factor VIII, Fetal Blood, Gene Therapy, Genetic Vectors, Hemophilia A, Humans, Infant, Newborn, Megakaryocytes, Membrane Proteins, Mice, Models, Biological, Promoter Regions (Genetics), Recombinant Proteins, Simian immunodeficiency virus, Stem Cell Factor, Thrombopoietin
Check for Full Text / PubMed Unique Identifier (PMID): 16723382
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.